1800465-47-7

Basic information

• Product Name: 13-(2-fluorobenzyl)-9,10-dimethoxy-5H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinoline-8(6H)-one
• CAS NO: 1800465-47-7
• Molecular Weight: 459.474
• Mol File: 1800465-47-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 13-(2-fluorobenzyl)-9,10-dimethoxy-5H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinoline-8(6H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 13-(2-fluorobenzyl)-9,10-dimethoxy-5H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinoline-8(6H)-one(1800465-47-7)
• EPA Substance Registry System: 13-(2-fluorobenzyl)-9,10-dimethoxy-5H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinoline-8(6H)-one(1800465-47-7)

Safety Data

• Hazardous Substances Data: 1800465-47-7(Hazardous Substances Data)

Usage

Molecular structure

A complex chemical compound with a long molecular structure.

Fluoro-substituted benzyl group

Contains a benzyl group substituted with a fluorine atom.

Methoxy groups

Has two methoxy (-OCH3) groups attached to the molecule.

Dioxolo ring system

Features a dioxolo (cyclic ether) ring system as part of its structure.

Type of isoquinoline

The compound belongs to the isoquinoline class of compounds.

Pharmaceutical applications

Has potential pharmaceutical applications due to its structural features.

Biological activity

May exhibit biological activity, which could be relevant for drug development.

Potential drug development

Could potentially be used in the development of new drugs.

Further research needed

Requires additional research and testing to determine specific properties and potential uses.

Upstream product

• 633-65-8 berberine chloride 
• 1390654-28-0 13-(2-fluorobenzyl)-9,10-dimethoxy-5H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinoline-7-iumbromide 

Relevant articles and documents

Novel 8-Oxoprotoberberine Derivative or Pharmaceutically Acceptable Salt Thereof, Preparation Method Therefor and Pharmaceutical Composition for Preventing or Treating Diseases Associated with Activity of NFAT5, Containing Same as Active Ingredient

The preset invention relates to a novel 8-oxoprotoberberine derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases associated with the activity of NFAT5 containing the same as an active ingredient. The novel 8-oxoproteoberberine derivative or the pharmaceutically acceptable salt thereof according to the present invention can be useful in a pharmaceutical composition for preventing or treating diseases associated with the activity of NFAT5, particularly rheumatoid arthritis or inflammatory diseases, since it is ascertained that the derivative or a pharmaceutically acceptable salt thereof has remarkably increased oral absorption compared with known protoberberine due to an improvement in the properties thereof, and inhibits the activity of NFAT5 and the secretion of inflammatory cytokines and reduces the expression of NAFT5 in mice with rheumatoid arthritis by directly inhibiting the transcription of NFT5.